Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. (PFE), headquartered at The Spiral in Manhattan, New York City, is a leading American multinational pharmaceutical and biotechnology corporation established in 1849 by Charles Pfizer and his cousin Charles F. Erhart. Pfizer stands as one of the world's largest pharmaceutical companies, with annual sales nearing $50 billion, excluding COVID-19 product sales.
Pfizer's core business revolves around the development, manufacturing, and global distribution of prescription drugs and vaccines. Its top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. These products contribute significantly to Pfizer's global sales, with nearly 50% of revenues coming from international markets, and emerging markets playing a crucial role.
In recent news, Pfizer continues to make strides in cancer treatment through its collaboration with Astellas and Merck. A key focus has been on the promising cancer therapeutic combinations involving PADCEV™ (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab), targeting metastatic urothelial cancer. This collaboration underscores Pfizer's commitment to advancing cancer treatments and improving patient outcomes worldwide.
Financially, Pfizer remains robust, continually investing in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs. Strategic partnerships and collaborations further enhance its position in the market, ensuring a steady pipeline of new and effective therapeutic solutions.
With a rich history and a steadfast commitment to healthcare innovation, Pfizer Inc. continues to be a significant player in the pharmaceutical industry, dedicated to improving global health through advanced medical research and groundbreaking therapies.
Pfizer and BioNTech announced positive results from their study of two Omicron-adapted COVID-19 vaccine candidates, a monovalent and a bivalent one. These candidates exhibited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg doses, respectively. The bivalent vaccine demonstrated a 9.1 and 10.9-fold increase against the same variant. Both candidates showed a favorable safety profile, and data will be discussed with regulatory authorities for potential emergency use authorization.
Pfizer Inc. (NYSE: PFE) is hosting a conference call on July 28, 2022, at 10 a.m. EDT to discuss its Second Quarter 2022 Performance Report. Investors and the public can access the event via webcast on Pfizer's investor website. To listen by phone, dial 800-456-4352 in the U.S. or 785-424-1086 internationally, using the password 'PFEQ222'. A transcript and replay will be available online within 24 hours after the call.
Pfizer continues its commitment to improving patient lives through innovative health care solutions.
Pfizer (NYSE: PFE) announced a
Pfizer has announced a €90.5 million ($95 million) investment in Valneva, acquiring an 8.1% stake in the company. This investment is aimed at supporting the development of VLA15, a Lyme disease vaccine candidate, with the Phase 3 study set to begin in Q3 2022. Pfizer will also update the collaboration agreement with Valneva, increasing Valneva's contribution to 40% of shared development costs. The total potential milestone payments to Valneva remain at $168 million, with royalties adjusted to a tiered range of 14% to 22%.
Pfizer Inc. and BioNTech SE have received FDA emergency use authorization for their COVID-19 vaccine, now available for children aged 6 months to 4 years. The 3-µg dose showed a strong immune response and a favorable safety profile similar to the placebo in a Phase 2/3 clinical trial involving 4,526 children. The trial demonstrated immunogenicity comparable to older age groups, meeting regulatory non-inferiority criteria. The vaccine rollout is anticipated to begin following CDC recommendations, ensuring free access for U.S. residents.
Pfizer's EPIC-SR study of PAXLOVID, targeting standard-risk COVID-19 patients, did not achieve its primary endpoint of sustained symptom relief. However, secondary analyses indicated a nominally significant 62% reduction in COVID-related medical visits. The company will halt enrollment in the EPIC-SR trial, focusing instead on high-risk populations due to low hospitalization rates. Data from this study will be included in the upcoming NDA submission to the FDA. Despite these challenges, Pfizer maintains that PAXLOVID's efficacy and safety profile is supported by data across multiple studies.
Pfizer, MorphoSys, and Incyte announced a clinical trial collaboration to explore the immunotherapeutic combination of Pfizer's TTI-622 with MorphoSys's Monjuvi and lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplantation. Pfizer will lead a multicenter Phase 1b/2 study, which is set to take place in North America, Europe, and Asia-Pacific. The initiative addresses significant unmet medical needs in DLBCL treatment and follows promising preclinical data regarding TTI-622's potential efficacy.
Pfizer (NYSE: PFE) has successfully acquired ReViral, a clinical-stage biopharmaceutical company specializing in antiviral therapeutics for respiratory syncytial virus (RSV), for up to $525 million. This acquisition enhances Pfizer's anti-infective pipeline with promising candidates like sisunatovir, which has shown significant efficacy in clinical studies. The potential annual revenue for these programs could exceed $1.5 billion. This strategic move underscores Pfizer's commitment to advancing innovative therapies for serious infectious diseases.
Pfizer Inc. (NYSE: PFE) will host a webcast on June 16, 2022, featuring Mikael Dolsten, Chief Scientific Officer, at the Storebrand Conference: Invest in the Future. The event starts at 11:40 a.m. CEST (5:40 a.m. EDT). Investors can access the live presentation and register through www.pfizer.com/investors. A transcript and replay will be available within 24 hours post-event for 90 days. Pfizer emphasizes its commitment to health advancements and innovation, impacting global healthcare.
Pfizer Inc. (NYSE: PFE) is hosting a webcast discussion with Chief Scientific Officer Mikael Dolsten and Chief Development Officer William Pao at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 8:40 a.m. PDT. Interested parties can access the webcast at www.pfizer.com/investors. The transcript will be available within 24 hours and accessible for at least 90 days. Pfizer focuses on innovative therapies and vaccines to enhance patient lives and actively engages in global health initiatives.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
What is Pfizer Inc. known for?
Where is Pfizer's headquarters located?
How much does Pfizer make annually?
What are some of Pfizer's top-selling products?
What is the significance of Pfizer's international sales?
What recent collaborations has Pfizer been involved in?
When was Pfizer founded?
What is Pfizer's approach to innovation?
How does Pfizer contribute to cancer treatment?
What role do strategic partnerships play for Pfizer?
